HER2-Directed Therapies in NSCLC: Navigating Clinical Insights, Integration Challenges, and Access Considerations : Episode 13
Opinion
Video
Emerging Horizons in HER2-Directed NSCLC Treatments
Key Takeaways
- Recent trials, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung 01, show promising results for HER2-directed therapies in NSCLC.
- Advancements in targeting HER2 mutations suggest potential improvements in treatment efficacy and patient outcomes.
A review of recent clinical trial results for emerging HER2-directed therapies, including SOHO-01, inetetamab/pyrotinib, and BEAMION Lung-01, and their potential impact on the future treatment landscape for HER2-positive NSCLC.
Video content above is prompted by the following:
- Several HER2-directed therapies are currently in development. Could you discuss the recent clinical trial results for emerging agents, such as those from the SOHO-01, the inetetamab/pyrotinib combination study, and the BEAMION Lung 01 data and what implications might these findings have for the future landscape of HER2-directed therapies in NSCLC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
